NO781035L - T fremgangsmaate til fremstilling av et farmasoeytisk prepara - Google Patents

T fremgangsmaate til fremstilling av et farmasoeytisk prepara

Info

Publication number: NO781035L
Authority: NO; Norway
Prior art keywords: extract; glucanase; physarum; fysarum; treatment
Prior art date: 1977-03-28

Application number

NO781035A

Other languages

English (en)

Norwegian (no)

Inventor

David Allen Lewis Davies

Anthony Michael Samuel Pope

Original Assignee

Searle & Co

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1977-03-28

Filing date

1978-03-22

Publication date

1978-09-29

1978-03-22 Application filed by Searle & Co filed Critical Searle & Co

1978-09-29 Publication of NO781035L publication Critical patent/NO781035L/no

Links

238000000034 method Methods 0.000 title claims description 16
239000000825 pharmaceutical preparation Substances 0.000 title claims description 7
239000000284 extract Substances 0.000 claims description 49
241000224485 Physarum Species 0.000 claims description 33
102000004190 Enzymes Human genes 0.000 claims description 32
108090000790 Enzymes Proteins 0.000 claims description 32
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical group O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 claims description 17
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 claims description 16
229960003942 amphotericin b Drugs 0.000 claims description 16
241001465754 Metazoa Species 0.000 claims description 14
230000000694 effects Effects 0.000 claims description 14
229940121375 antifungal agent Drugs 0.000 claims description 12
238000011282 treatment Methods 0.000 claims description 12
238000002360 preparation method Methods 0.000 claims description 10
230000000843 anti-fungal effect Effects 0.000 claims description 8
239000003429 antifungal agent Substances 0.000 claims description 8
229960000988 nystatin Drugs 0.000 claims description 8
VQOXZBDYSJBXMA-NQTDYLQESA-N nystatin A1 Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/CC/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 VQOXZBDYSJBXMA-NQTDYLQESA-N 0.000 claims description 8
206010017533 Fungal infection Diseases 0.000 claims description 6
238000004519 manufacturing process Methods 0.000 claims description 6
102000012286 Chitinases Human genes 0.000 claims description 4
108010022172 Chitinases Proteins 0.000 claims description 4
208000031888 Mycoses Diseases 0.000 claims description 4
239000003937 drug carrier Substances 0.000 claims description 4
108010055851 Acetylglucosaminidase Proteins 0.000 claims description 3
102100036495 Di-N-acetylchitobiase Human genes 0.000 claims description 2
XRECTZIEBJDKEO-UHFFFAOYSA-N flucytosine Chemical compound NC1=NC(=O)NC=C1F XRECTZIEBJDKEO-UHFFFAOYSA-N 0.000 claims description 2
229960004413 flucytosine Drugs 0.000 claims description 2
230000001878 mycolytic effect Effects 0.000 claims 3
229940088598 enzyme Drugs 0.000 description 24
FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 23
LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 12
208000015181 infectious disease Diseases 0.000 description 11
239000011780 sodium chloride Substances 0.000 description 10
108010014251 Muramidase Proteins 0.000 description 8
102000016943 Muramidase Human genes 0.000 description 8
108010062010 N-Acetylmuramoyl-L-alanine Amidase Proteins 0.000 description 8
210000004027 cell Anatomy 0.000 description 8
235000010335 lysozyme Nutrition 0.000 description 7
241000222511 Coprinus Species 0.000 description 6
239000007788 liquid Substances 0.000 description 6
241000699670 Mus sp. Species 0.000 description 5
230000002538 fungal effect Effects 0.000 description 5
229940051921 muramidase Drugs 0.000 description 5
239000000725 suspension Substances 0.000 description 5
238000002560 therapeutic procedure Methods 0.000 description 5
230000002101 lytic effect Effects 0.000 description 4
239000000243 solution Substances 0.000 description 4
241001225321 Aspergillus fumigatus Species 0.000 description 3
208000036641 Aspergillus infections Diseases 0.000 description 3
241000224486 Physarum polycephalum Species 0.000 description 3
HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
230000001580 bacterial effect Effects 0.000 description 3
210000002421 cell wall Anatomy 0.000 description 3
239000000287 crude extract Substances 0.000 description 3
229940079593 drug Drugs 0.000 description 3
239000003814 drug Substances 0.000 description 3
239000007928 intraperitoneal injection Substances 0.000 description 3
239000000203 mixture Substances 0.000 description 3
239000000047 product Substances 0.000 description 3
239000000126 substance Substances 0.000 description 3
CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
201000002909 Aspergillosis Diseases 0.000 description 2
241000228212 Aspergillus Species 0.000 description 2
238000011725 BALB/c mouse Methods 0.000 description 2
241000222120 Candida <Saccharomycetales> Species 0.000 description 2
241000222122 Candida albicans Species 0.000 description 2
241000700198 Cavia Species 0.000 description 2
241000233866 Fungi Species 0.000 description 2
241000192041 Micrococcus Species 0.000 description 2
230000000844 anti-bacterial effect Effects 0.000 description 2
238000005119 centrifugation Methods 0.000 description 2
230000034994 death Effects 0.000 description 2
231100000517 death Toxicity 0.000 description 2
208000024386 fungal infectious disease Diseases 0.000 description 2
238000000338 in vitro Methods 0.000 description 2
238000001990 intravenous administration Methods 0.000 description 2
229960000274 lysozyme Drugs 0.000 description 2
239000004325 lysozyme Substances 0.000 description 2
239000000463 material Substances 0.000 description 2
230000003287 optical effect Effects 0.000 description 2
241000894007 species Species 0.000 description 2
239000006228 supernatant Substances 0.000 description 2
239000013589 supplement Substances 0.000 description 2
230000002195 synergetic effect Effects 0.000 description 2
230000000699 topical effect Effects 0.000 description 2
OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 1
229930183010 Amphotericin Natural products 0.000 description 1
QGGFZZLFKABGNL-UHFFFAOYSA-N Amphotericin A Natural products OC1C(N)C(O)C(C)OC1OC1C=CC=CC=CC=CCCC=CC=CC(C)C(O)C(C)C(C)OC(=O)CC(O)CC(O)CCC(O)C(O)CC(O)CC(O)(CC(O)C2C(O)=O)OC2C1 QGGFZZLFKABGNL-UHFFFAOYSA-N 0.000 description 1
241000894006 Bacteria Species 0.000 description 1
206010007134 Candida infections Diseases 0.000 description 1
241000288673 Chiroptera Species 0.000 description 1
101000925662 Enterobacteria phage PRD1 Endolysin Proteins 0.000 description 1
WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
241000222065 Lycoperdon Species 0.000 description 1
241000282560 Macaca mulatta Species 0.000 description 1
GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
206010067482 No adverse event Diseases 0.000 description 1
240000007594 Oryza sativa Species 0.000 description 1
240000004808 Saccharomyces cerevisiae Species 0.000 description 1
241001302210 Sida <water flea> Species 0.000 description 1
229920002125 Sokalan® Polymers 0.000 description 1
229920002472 Starch Polymers 0.000 description 1
241000223238 Trichophyton Species 0.000 description 1
241001045770 Trichophyton mentagrophytes Species 0.000 description 1
206010067409 Trichophytosis Diseases 0.000 description 1
230000005856 abnormality Effects 0.000 description 1
238000001042 affinity chromatography Methods 0.000 description 1
BFNBIHQBYMNNAN-UHFFFAOYSA-N ammonium sulfate Chemical compound N.N.OS(O)(=O)=O BFNBIHQBYMNNAN-UHFFFAOYSA-N 0.000 description 1
229910052921 ammonium sulfate Inorganic materials 0.000 description 1
235000011130 ammonium sulphate Nutrition 0.000 description 1
229940009444 amphotericin Drugs 0.000 description 1
238000011888 autopsy Methods 0.000 description 1
230000003115 biocidal effect Effects 0.000 description 1
230000037396 body weight Effects 0.000 description 1
229940095731 candida albicans Drugs 0.000 description 1
201000003984 candidiasis Diseases 0.000 description 1
150000001720 carbohydrates Chemical class 0.000 description 1
235000014633 carbohydrates Nutrition 0.000 description 1
239000003795 chemical substances by application Substances 0.000 description 1
150000001875 compounds Chemical class 0.000 description 1
239000013068 control sample Substances 0.000 description 1
238000007796 conventional method Methods 0.000 description 1
239000012228 culture supernatant Substances 0.000 description 1
238000005520 cutting process Methods 0.000 description 1
230000000593 degrading effect Effects 0.000 description 1
239000012153 distilled water Substances 0.000 description 1
239000002552 dosage form Substances 0.000 description 1
238000002474 experimental method Methods 0.000 description 1
238000000605 extraction Methods 0.000 description 1
238000000855 fermentation Methods 0.000 description 1
230000004151 fermentation Effects 0.000 description 1
244000053095 fungal pathogen Species 0.000 description 1
230000000855 fungicidal effect Effects 0.000 description 1
239000000417 fungicide Substances 0.000 description 1
229940049735 fusarium extract Drugs 0.000 description 1
229930182830 galactose Natural products 0.000 description 1
238000001641 gel filtration chromatography Methods 0.000 description 1
239000008103 glucose Substances 0.000 description 1
150000004676 glycans Chemical class 0.000 description 1
238000011534 incubation Methods 0.000 description 1
230000002401 inhibitory effect Effects 0.000 description 1
238000011081 inoculation Methods 0.000 description 1
238000007912 intraperitoneal administration Methods 0.000 description 1
238000010253 intravenous injection Methods 0.000 description 1
238000002955 isolation Methods 0.000 description 1
238000009630 liquid culture Methods 0.000 description 1
231100000053 low toxicity Toxicity 0.000 description 1
238000005259 measurement Methods 0.000 description 1
238000002844 melting Methods 0.000 description 1
230000008018 melting Effects 0.000 description 1
238000005374 membrane filtration Methods 0.000 description 1
239000003604 miotic agent Substances 0.000 description 1
238000006213 oxygenation reaction Methods 0.000 description 1
244000052769 pathogen Species 0.000 description 1
230000001717 pathogenic effect Effects 0.000 description 1
239000000902 placebo Substances 0.000 description 1
229940068196 placebo Drugs 0.000 description 1
229920001282 polysaccharide Polymers 0.000 description 1
239000005017 polysaccharide Substances 0.000 description 1
239000002244 precipitate Substances 0.000 description 1
238000001556 precipitation Methods 0.000 description 1
102000004169 proteins and genes Human genes 0.000 description 1
108090000623 proteins and genes Proteins 0.000 description 1
230000002685 pulmonary effect Effects 0.000 description 1
239000012521 purified sample Substances 0.000 description 1
230000002829 reductive effect Effects 0.000 description 1
210000005084 renal tissue Anatomy 0.000 description 1
230000029058 respiratory gaseous exchange Effects 0.000 description 1
238000000926 separation method Methods 0.000 description 1
239000007787 solid Substances 0.000 description 1
238000001228 spectrum Methods 0.000 description 1
235000019698 starch Nutrition 0.000 description 1
239000008107 starch Substances 0.000 description 1
230000004083 survival effect Effects 0.000 description 1
238000011287 therapeutic dose Methods 0.000 description 1
210000001519 tissue Anatomy 0.000 description 1
231100000331 toxic Toxicity 0.000 description 1
230000002588 toxic effect Effects 0.000 description 1
231100000820 toxicity test Toxicity 0.000 description 1
210000003462 vein Anatomy 0.000 description 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
238000005303 weighing Methods 0.000 description 1
210000005253 yeast cell Anatomy 0.000 description 1

Classifications

- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01108—Lactase (3.2.1.108)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/24—Hydrolases (3) acting on glycosyl compounds (3.2)
- C12N9/2402—Hydrolases (3) acting on glycosyl compounds (3.2) hydrolysing O- and S- glycosyl compounds (3.2.1)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01021—Beta-glucosidase (3.2.1.21)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01023—Beta-galactosidase (3.2.1.23), i.e. exo-(1-->4)-beta-D-galactanase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01025—Beta-mannosidase (3.2.1.25), i.e. mannanase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01039—Glucan endo-1,3-beta-D-glucosidase (3.2.1.39)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01052—Beta-N-acetylhexosaminidase (3.2.1.52)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01058—Glucan 1,3-beta-glucosidase (3.2.1.58)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01073—Licheninase (3.2.1.73)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01075—Glucan endo-1,6-beta-glucosidase (3.2.1.75)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01078—Mannan endo-1,4-beta-mannosidase (3.2.1.78), i.e. endo-beta-mannanase
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Y—ENZYMES
- C12Y302/00—Hydrolases acting on glycosyl compounds, i.e. glycosylases (3.2)
- C12Y302/01—Glycosidases, i.e. enzymes hydrolysing O- and S-glycosyl compounds (3.2.1)
- C12Y302/01084—Glucan 1,3-alpha-glucosidase (3.2.1.84), i.e. mutanase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides

Landscapes

Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Zoology (AREA)
Wood Science & Technology (AREA)
Genetics & Genomics (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
Biochemistry (AREA)
General Engineering & Computer Science (AREA)
Medicinal Chemistry (AREA)
Communicable Diseases (AREA)
Veterinary Medicine (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Public Health (AREA)
General Chemical & Material Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Chemical Kinetics & Catalysis (AREA)
Oncology (AREA)
Animal Behavior & Ethology (AREA)
Molecular Biology (AREA)
Biomedical Technology (AREA)
Biotechnology (AREA)
Microbiology (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Enzymes And Modification Thereof (AREA)
Medicines Containing Plant Substances (AREA)
Medicinal Preparation (AREA)
Medicines Containing Material From Animals Or Micro-Organisms (AREA)

NO781035A 1977-03-28 1978-03-22 T fremgangsmaate til fremstilling av et farmasoeytisk prepara NO781035L (no)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
GB12919/77A GB1576891A (en)	1977-03-28	1977-03-28	Antimicrobial compositions containing extracts of light enzymes from physarum species

Publications (1)

Publication Number	Publication Date
NO781035L true NO781035L (no)	1978-09-29

Family

ID=10013545

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO781035A NO781035L (no)	1977-03-28	1978-03-22	T fremgangsmaate til fremstilling av et farmasoeytisk prepara

Country Status (20)

Country	Link
JP (1)	JPS542310A (de)
AT (1)	AT363589B (de)
AU (1)	AU519066B2 (de)
BE (1)	BE865369A (de)
CA (1)	CA1107646A (de)
DE (1)	DE2813282A1 (de)
DK (1)	DK134678A (de)
ES (1)	ES468236A1 (de)
FI (1)	FI780933A7 (de)
FR (1)	FR2385730A1 (de)
GB (1)	GB1576891A (de)
GR (1)	GR71706B (de)
IE (1)	IE46698B1 (de)
IL (1)	IL54364A0 (de)
NL (1)	NL7803291A (de)
NO (1)	NO781035L (de)
NZ (1)	NZ186783A (de)
PT (1)	PT67826B (de)
SE (1)	SE7803456L (de)
ZA (1)	ZA781758B (de)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
JPS58134014A (ja) *	1982-02-03	1983-08-10	Rooto Seiyaku Kk	義歯洗浄用組成物
US4542020A (en) *	1984-08-17	1985-09-17	E. R. Squibb & Sons, Inc.	Long-lasting adhesive antifungal suppositories
JPH0261164A (ja) *	1988-08-27	1990-03-01	Hisaka Works Ltd	処理槽への内槽装填・取り出し方法およびそれに用いる移載車。
JPH0261163A (ja) *	1988-08-27	1990-03-01	Hisaka Works Ltd	繊維材料取り出し方法およびそれに用いる装置
EP0906020B1 (de) *	1996-06-07	2002-02-06	Dsm N.V.	Verwendung einer fungiziden zusammensetzung als pflanzenschutzmittel

1977
- 1977-03-28 GB GB12919/77A patent/GB1576891A/en not_active Expired
1978
- 1978-03-22 NO NO781035A patent/NO781035L/no unknown
- 1978-03-23 NZ NZ186783A patent/NZ186783A/xx unknown
- 1978-03-23 AU AU34479/78A patent/AU519066B2/en not_active Expired
- 1978-03-27 IL IL54364A patent/IL54364A0/xx unknown
- 1978-03-27 ES ES468236A patent/ES468236A1/es not_active Expired
- 1978-03-27 JP JP3526978A patent/JPS542310A/ja active Pending
- 1978-03-27 PT PT67826A patent/PT67826B/pt unknown
- 1978-03-27 GR GR55801A patent/GR71706B/el unknown
- 1978-03-28 DE DE19782813282 patent/DE2813282A1/de not_active Withdrawn
- 1978-03-28 BE BE186314A patent/BE865369A/xx unknown
- 1978-03-28 SE SE7803456A patent/SE7803456L/xx unknown
- 1978-03-28 FR FR7808962A patent/FR2385730A1/fr active Granted
- 1978-03-28 DK DK134678A patent/DK134678A/da not_active Application Discontinuation
- 1978-03-28 CA CA299,788A patent/CA1107646A/en not_active Expired
- 1978-03-28 FI FI780933A patent/FI780933A7/fi not_active Application Discontinuation
- 1978-03-28 ZA ZA00781758A patent/ZA781758B/xx unknown
- 1978-03-28 NL NL7803291A patent/NL7803291A/xx not_active Application Discontinuation
- 1978-03-28 AT AT0215978A patent/AT363589B/de not_active IP Right Cessation
- 1978-03-29 IE IE623/78A patent/IE46698B1/en unknown

Also Published As

Publication number	Publication date
ES468236A1 (es)	1978-12-01
PT67826A (en)	1978-04-01
JPS542310A (en)	1979-01-09
DE2813282A1 (de)	1978-10-12
NL7803291A (nl)	1978-10-02
IE46698B1 (en)	1983-08-24
GB1576891A (en)	1980-10-15
FI780933A7 (fi)	1978-09-29
DK134678A (da)	1978-09-29
ZA781758B (en)	1979-05-30
AT363589B (de)	1981-08-10
BE865369A (fr)	1978-09-28
FR2385730A1 (fr)	1978-10-27
NZ186783A (en)	1980-12-19
AU3447978A (en)	1979-09-27
PT67826B (en)	1979-09-27
CA1107646A (en)	1981-08-25
FR2385730B1 (de)	1981-07-10
IL54364A0 (en)	1978-06-15
IE780623L (en)	1978-09-28
GR71706B (de)	1983-06-21
SE7803456L (sv)	1978-09-29
ATA215978A (de)	1981-01-15
AU519066B2 (en)	1981-11-05

Publication	Publication Date	Title
US4062941A (en)	1977-12-13	Method for treating fungal infections using cell lytic enzymes
Ashby	1927	Macrophomina phaseoli (Maubl.) comb. nov., the pycnidial stage of Rhizoctonia bataticola (Taub.) Butl
DE3688710T2 (de)	1993-11-18	Isolierung und pharmazeutische Verwendung von Hyaluronidase und diese enthaltende pharmazeutische und tierärztliche Präparate.
Kobayashi et al.	1972	Amphotericin B potentiation of rifampicin as an antifungal agent against the yeast phase of Histoplasma capsulatum
KR20140135210A (ko)	2014-11-25	바실러스, 히알루론산 효소, 및 그의 용도
US4985543A (en)	1991-01-15	Lectins and antiretroviral drugs containing the lectins as active ingredient
Budtz-Jörgensen	1974	Proteolytic activity of Candida spp. as related to the pathogenesis of denture stomatitis
Ginsburg et al.	1960	Effect of streptococcal haemolysins on Ehrlich ascites tumour cells
Felton et al.	1979	Vitreous inhibition of tumor neovascularization
Toews et al.	1985	Role of C5 and recruited neutrophils in early clearance of nontypable Haemophilus influenzae from murine lungs
KR0149477B1 (ko)	1998-10-15	Hiv 활성의 저해제
NO781035L (no)	1978-09-29	T fremgangsmaate til fremstilling av et farmasoeytisk prepara
US4144327A (en)	1979-03-13	Antimicrobial composition comprising lytic enzymes from physarum and an antimycotic agent
EP0201332A2 (de)	1986-11-12	Gegen Infektionen aktive Verbindung
WO1999058650A1 (en)	1999-11-18	Lytic enzymes useful for treating fungal infections
DE2048848A1 (de)	1971-05-19	Verfahren zur Herstellung eines Korn plexes aus RNS und Polysacchand, Verfahren zur Gewinnung der Polysacchand Komponente und ihre Verwendung zur Herstellung von Arzneimitteln
Watanabe et al.	1980	Cytotoxicity of pyocin S2 to tumor and normal cells and its interaction with cell surfaces
Sulkin et al.	1957	Effect of zymosan on bacteriophage clearance
DE69617956T2 (de)	2004-08-19	Zusammensetzungen, welche adp-ribosyltransferase-aktivität aufweisen und methoden für ihre herstellung und die verwendung derselben
Whitehouse	1962	Structure-action relationships among drugs acting on connective tissues (anti-rheumatic agents)
EP1062947A1 (de)	2000-12-27	Arzneimittel für aids
US6020325A (en)	2000-02-01	Method for inhibiting replication of HIV
Sen et al.	1952	Reversal of the diabetogenic action of alloxan by sulfhydryl compounds
Rangarajan et al.	1971	Erwinia carotovora (Jones) Holland as the inciting agent of Corn stalk rot in India
SISSON et al.	1974	Inhibition of Glycosaminoglycans Production in Retrohulbar Fibroblast Cultures by Ethacrynic Acid and Hydrocortisone